Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience. (November 2022) - Caldart, A.; Fiorio, E.; Zanelli, S.; Biondani, P.; Parolin, V.; Pellini, F.; Montemezzi, S.; Nottegar, A.; Caliò, A.; Zampiva, I.; Merler, S.; Mongillo, M.; et al.